US FDA delays decision on Novartis COPD drug, giving Forest drug a leap ahead
This article was originally published in Scrip
Executive Summary
The US FDA needs three more months to complete its review of Novartis' investigational chronic obstructive pulmonary disease (COPD) drug indacaterol (QAB149), the company said.